Loading...
  • followed by stem cell
  • Consolidation therapy followed by stem cell rescue repeats every 28 days for 3 courses (C) and 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks (R), the order of which depends on patient age, in the absence of disease progression or unacceptable toxicity. (clinicaltrials.gov)
  • granulocyte
  • A medication referred to as granulocyte colony-stimulating factor (Neupogen) is usually given daily for 4 or 5 days by injection, in order to increase the number of stem cells present in your blood. (verywellhealth.com)
  • At one time it was thought that granulocyte stimulating factor may increase the risk of leukemia in those who received it, but that does not appear to be the case, and in one large study the incidence of leukemia in people who had received granulocyte stimulating factor in preparation for donating stem cells was actually lower than the average in the population. (verywellhealth.com)
  • The most bothersome side effects of a stem cell donation usually occur in the days before the donation and are related to the side effects of the injections of granulocyte stimulating factor. (verywellhealth.com)
  • We conclude that long-term marrow repopulating cells mobilized into circulation by treatment with granulocyte colony-stimulating factor (G-CSF ) and stem cell factor (SCF ) are capable of maintaining lifelong polyclonal hematopoiesis in reconstituted mice. (bloodjournal.org)
  • Granulocyte colony-stimulating factor (G-CSF ) in combination with stem cell factor (SCF ) mobilizes more primitive HSC than each factor alone in nonhuman primates, dogs, and mice. (bloodjournal.org)
  • 95% donor CD3+ T cells and mixed chimerism is the detection of peripheral blood donor T cells (CD3+) and granulocytes (CD33+) as a proportion of the total peripheral blood T cell and granulocyte population, respectively. (clinicaltrials.gov)
  • clinical
  • Although stem cell-based treatments for stroke and other neurodegenerative diseases have advanced rapidly, there are still few clinical treatments available. (jneurosci.org)
  • radiation
  • I. To determine the 6-, 12-, and 24-month event-free survival and overall survival of children (birth to 21 years of age) with atypical teratoid/rhabdoid CNS tumors (AT/RT), diagnosed based on histology, immunophenotyping, and modern molecular and immunohistochemical analysis of INI1, treated with surgery, intensive chemotherapy combined with stem cell rescue, and radiation therapy. (clinicaltrials.gov)
  • Treatment
  • Dr. Willing and her colleagues wanted to explore whether G-CSF treated peripheral blood cells might also be a treatment for central nervous system disorders. (innovations-report.com)
  • Our findings suggest that mobilized peripheral blood cells might be a good candidate for early treatment of central nervous system disorders like stroke," said Paul R. Sanberg, PhD, DSc, professor of neurosurgery and director of the USF Center for Aging and Brain Repair. (innovations-report.com)
  • Following this experimental treatment, the patient will be given the stem cells through a central venous catheter (tube inserted in a vein). (clinicaltrials.gov)
  • To estimate the effect of HIV infection on the presence of HIV-resistant blood cells as measured by genetic marking for vector sequences before and after antiviral treatment interruption. (clinicaltrials.gov)